Company
Brainq Technologies
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
0
510(k), De Novo and PMA
Device trials
4
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Brainq Technologies, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Brainq Technologies.
Latest FDA decisions
No 510(k), De Novo or PMA decisions under this name since 2015.
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute TreatmentPivotal-lookingTerminated
NCT06386874 · 62 participants · Start Aug 20, 2024 · Primary completion Dec 26, 2025
Device: Q Therapeutic System (BQ 3.0) - Sham; Q Therapeutic System (BQ 3.0) - Active · For: Ischemic Stroke
Sites: Downey, California; Washington D.C., District of Columbia; Jacksonville, Florida · 14 sites in all
- The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)Pivotal-lookingCompleted
NCT05044507 · 100 participants · Start Dec 4, 2021 · Primary completion Nov 6, 2023
Device: BQ 2.0; BQ 2.0 · For: Ischemic Stroke
Sites: Downey, California; Los Angeles, California; Washington D.C., District of Columbia · 15 sites in all
- The Use of Electromagnetic Field (EMF) Treatment in Chronic Spinal Cord Injury (SCI) PatientsStatus unknown
NCT04050696 · 8 participants (planned) · Start Sep 18, 2019 · Primary completion Dec 1, 2023
Device: BQ 1.2 · For: Incomplete Spinal Cord Injury
Sites: Miami, Florida; West Orange, New Jersey; Ramat Gan, Israel
1 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.